Bayer stock gets U.S. approval for first Factor XIa drug

Bayer's Pharmaceuticals division received U.S. approval for Sunharbo on November 9, 2026, and Bayer announced the decision on November 10. The U.S. Food and Drug Administration authorized the 50-milligram asundexian tablet in combination with antiplatelet therapy for adults following a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.

Bayer said in its announcement that Sunharbo is the first approved Factor XIa inhibitor worldwide. The medicine is designed to inhibit Factor XIa, a protein involved in the blood coagulation pathway, while targeting clot formation associated with ischemic stroke.

Clinical evidence supports the approval

The approval rests on the Phase 3 OCEANIC-STROKE study, which randomized 12,327 participants internationally. Bayer said the trial demonstrated superiority in reducing ischemic stroke when asundexian was combined with antiplatelet therapy, compared with antiplatelet therapy alone.

Asundexian reduced ischemic stroke by 26 percent in patients who had suffered a non-cardioembolic ischemic stroke or a high-risk TIA. Bayer also reported a similar rate of major bleeding under the ISTH classification between asundexian and placebo. The FDA approval therefore gives Bayer a commercial foothold in a new treatment class, although the label applies to a defined patient group and does not cover stroke prevention in atrial fibrillation.

Commercial opportunity and execution

Bayer said Sunharbo has also been approved in China and that applications in additional markets are under review. The breadth and timing of those decisions will determine how quickly the new product can contribute to Pharmaceuticals revenue.

The drug adds a potential growth driver to Bayer's cardiovascular and cerebrovascular portfolio. Investors still need to weigh the opportunity against the company's broader execution demands, including the conversion of clinical differentiation into prescription uptake and reimbursement. The FDA decision is a regulatory milestone, not a forecast of sales or earnings.

Bayer stock traded at 56.88 euros on Lang & Schwarz at 10:10 CET on Wednesday, November 11, 0.35 percent below the Xetra close of Tuesday, November 10. The move provides the market context for the approval but does not establish a causal reaction to the regulatory decision.

The DAX provides the broader German market backdrop for Bayer stock. Current market reports.

More news and analyses on Bayer stock.